Obermatt
See Similar Stocks →

Maravai LifeSciences Holdings

NSQ:MRVI · US56600D1072
Life Sciences Tools & ServicesMedium

360

35
Profit price78
Owner Earnings Yield1
Dividend Yield1
Price/Sales60
EV / Gross Profit18
Price/Book37
Return on Capital38
Cash Return on Capital41
Return on Equity18
EBIT Margin20
Gross Profitability18
Accruals49
Owner Earnings Margin26
Sales growth52
Profit growth38
Reinvestment4
Price momentum87
Debt load41
Refinancing88
Debt Payback1
Liquidity38
Analyst ratings34
Opinion Changes50
Price Target Upside28
Market mood3
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Maravai LifeSciences Holdings doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2020
Employees74
Websitemaravai.com
ISINUS56600D1072
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyStem Cell TherapyHealth DiagnosticsOncologyVaccinesGenetics

Description

Maravai LifeSciences Holdings, Inc. (‘Maravai’), a life sciences company, provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The company’s solutions empower res…

Analysis

Middle-of-the-road

Maravai LifeSciences Holdings, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is stretched. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
43
2026

All-time high

68

Mar 2026

All-time low

43

Jun 2026

Average rank

56

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
60
—
—
—
Price/Earnings
86
—
—
—
Price/Book
37
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
71
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Maravai LifeSciences Holdings with its peers
Moderna
NSQ:MRNA
20
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Xeris Pharmaceuticals
NSQ:XERS
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sarepta Therapeutics
NSQ:SRPT
69
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Novavax
NSQ:NVAX
23
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
PTC Therapeutics
NSQ:PTCT
12
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →